People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Chinook Therapeutics U.S., Inc. | — | Biotechnology | Series D+ | $180.0M | $4.5B | 2019 |
| A2 Biotherapeutics, Inc. | — | Biotechnology | Series C | $143.1M | $1.2B | 2020 |
Srini Akkaraju at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Srini Akkaraju on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| David Goeddel | 1 | 10 |
| Srinivas Akkaraju | 1 | 10 |
| Helen S. Kim | 1 | 6 |
| Jeremy Caldwell | 1 | 4 |
| Sam Hall | 1 | 3 |
| Andrew King | 1 | 3 |
| Madhavan Balachandran | 1 | 3 |
| Preston Klassen | 1 | 2 |
| Paul Eisenberg | 1 | 2 |
| Susan L. Kelley | 1 | 2 |
| Jakob S. Loven | 1 | 2 |
| Alan Glicklich | 1 | 1 |
| Scott Foraker | 1 | 1 |
| David S. Lucas | 1 | 1 |
| William S. Go | 1 | 1 |
| Thomas S. Leung | 1 | 1 |
| Alexander Kamb | 1 | 1 |
| Michael Gallo | 1 | 1 |
| C. Alexander Kamb | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.